Clinical Trials | April 16, 2024
Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
Global Phase-3 study initiation expected in the second half of 2024
Global Phase-3 study initiation expected in the second half of 2024
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
New Board of Directors and management team at Suven Pharma also appointed
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
Suven Life Sciences has reported total income of Rs. 9.43 crores during the period ended June 30, 2023
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
